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Different species belonging to the genus Lycopodium L. (Lycopodiaceae) were used in 
folk medicine due to their antibacterial, healing effects on wounds, and properties used in 
the treatment of mental diseases, like amnesia, schizophrenia and different types of 
dementia. 
 Extracts containing volatiles obtained from different Lycopodium species: L. 
clavatum, L. annotinum, and Huperzia serrata (syn. Lycopodium serratum Thunb.), were 
tested against Mycobacterium tuberculosis. Dichloromethane and petroleum ether 
extracts of the mentioned species collected in different geographical sites (in Poland and 
Ukraine) have shown interesting activities. 
 Minimal Inhibitory Concentrations (MIC) values for the extracts were 
determined by a 96-well microplate method with alamarBlue (Invitrogen). The inoculum 
of the reference strain of Mycobacterium tuberculosis H37Ra in Middlebrook 7H9 broth 
(Difco) was 5 x 10
5
 cfu/mL per well, according to CLSI standards. Serial twofold 
dilutions of the extracts ranged from 8 to 256 µg/mL. As the internal control of the 
method, serial twofold dilutions of four first-line antibiotics dedicated to tuberculosis 
treatment: isoniazid (INH), rifampicin (RMP), ethambutol (EMB), and streptomycin 
(SM) were used [1,2]. 
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